Translational and Personalized Medicine

  • Krešimir Pavelić University of Rijeka, Department of Biotechnology
  • Tamara Martinović University of Rijeka, Department of Biotechnology
  • Sandra Kraljević Pavelić University of Rijeka, Department of Biotechnology
Keywords: personalized medicine, translational medicine, clinic, high-throughput methods, systems biology


The idea behind personalized medicine is to tailor health care to an individual’s unique genetic makeup. Hitherto, “one size fits all” approach was used in medicine. With the rise of personal medicine, we are moving towards a more precise, predictable and powerful medicine that is customized for each individual patient. To allow for an improvement in the acceleration and efficacy of drug development, high-throughput methods (“omics”) are rapidly being developed. This leads to understanding of multiple factors that are involved in disease progress on an individual level. In order to analyze the great amount of data that is collected from such experiments, one has to turn to systems biology, an interdisciplinary science that studies complex interactions within a biological system. Finally, translational medicine comes into play, by “translating” the information gathered from research into diagnostic tools, medicines and policies, with the final goal of improving individuals’ health. Personalized medicine is one of the future, and it will revolutionize the current practice of diagnosis-based medicine, once fully developed.


Download data is not yet available.


Bošnjak, H., Pavelić, K. & Kraljevic Pavelic, S. (2008) Towards preventive medicine, EMBO Reports, 9(11), pp. 1056-1060, doi: 10.1038/embor.2008.198.

Chin, L., Andersen, J. N. & Futreal, P. A. (2011) Does comparative-effectiveness research threaten personalized medicine? Nature Medicine (2011), 17: 297–303.

ESF Forward Look (2012) Personalized medicine for the European citizen. Toward more precize medicine for the diagnosis, treatment and prevention of disease (iPM), (Strasbourg: European Science Foundation), available at: (March 27, 2015).

Feldman, E. A. (2012) The Genetic Information Nondiscrimination Act (GINA): Public policy and medical practice in the age of personalized medicine, Journal of General Internal Medicine, 27(6), pp. 743–746, doi: 10.1007/s11606-012-1988-6.

Hamburg, M. A. & Collins, F. S (2010) The path to personalized medicine, New England Journal of Medicine, 363(4), pp. 301-304, doi: 10.1056/NEJMp1006304.

Katsios, C. & Roukos, D. H. (2010) Individual genomes and personalized medicine: life diversity and complexity, Personalized Medicine, 7(4), pp. 347-350, doi: 10.2217/pme.10.30.

Kraljević, S., Stambrook, P. & Pavelić, K (2004) Accelerating drug discovery, EMBO Reports 2004, 5(9), pp. 837-842, doi: 10.1038/sj.embor.7400236.

Longo, S. L. (2012) Tumor heterogeneity and personalized medicine, New England Journal of Medicine, 366(10), pp. 956-957, doi: 10.1056/NEJMe1200656.

McCarty, C. A., Wilke, R. A., Giampietro, P. F., Wesbrook, S. D. & Caldwell, M. D. (2005) Marshfield Clinic Personalized Medicine Research Project (PMRP): design, methods and recruitment for a large population-based biobank, Future Medicine, 2(1), pp. 49-79, doi: 10.1517/17410541.2.1.49.

Mirnezami, R., Nicholson, J. & Darzi, A. (2012) Preparing for Precision Medicine, New England Journal of Medicine, 366 (6), pp. 489-491, doi: 10.1056/NEJMp1114866.

Ng, P. C., Murray, S. S., Levy, S. & Venter, J. C. (2009) An agenda for personalized medicine, Nature, 461, pp. 724-726, doi:10.1038/461724a.

Parkinson, D. R., Johnson, B. E., Sledge, G. W. (2012) Making Personalized Cancer Medicine a Reality: Challenges and Opportunities in the Development of Biomarkers and Companion Diagnostics, Clinical Cancer Research, 18(3), pp. 619–624, doi: 10.1158/1078-0432.CCR-11-2017.

Sadée, W. & Dai, Z. (2005) Pharmacogenetics/genomics and personalized medicine, Human Molecular Genetics, 14(2), pp. R207–R214.

Simmons, L. A., Dinan, M. A., Robinson, T. J. & Snyderman, R (2012) Personalized medicine is more than genomic medicine: confusion over terminology impedes progress towards personalized healthcare, Future Medicine, 9(1), pp. 85-91, doi: 10.2217/pme.11.86.

Spira, A., Beane, J. E., Shah, V., Steiling, K., Gang Liu, G., Schembri, F., Gilman, S., Dumas Y.-M., Calner, P., Sebastiani, P., Sridhar, S., Beamis, J., Lamb, C., Anderson, T., Gerry, N., Keane, J., Lenburg, M. E. & Brody, J. S. (2007) Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer, Nature Medicine, 13(3), pp. 361 – 366.

Yan, Q. (2011) Toward the integration of personalized and systems medicine: challenges, opportunities and approaches, Personalized Medicine, 8(1), pp. 1-4, doi: 10.2217/pme.10.77.

Weston, A. D. & Hood, L. (2004) Systems Biology, Proteomics, and the Future of Health Care:Toward Predictive, Preventative, and Personalized Medicine. Journal of Proteome Research, 3(2), pp. 179-196.

Whirl-Carrillo, M., McDonagh, E. M., Hebert J. M., Gong, L., Sangkuhl, K., Thorn C. F., Altman, R. B. & Klein, T. E. (2012) Pharmacogenomics knowledge for personalized medicine, Clinical Pharmacology & Therapeutics, 92(4), pp. 414-417, doi: 10.1038/clpt.2012.96.

How to Cite
Pavelić K., Martinović T., & Pavelić S. K. (2015). Translational and Personalized Medicine. Medicine, Law & Society, 8(1), 25-33.